NCT04208087View on ClinicalTrials.gov

PK and Safety of SI-722 in IC/BPS

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 30, 2020

Primary Completion Date

January 12, 2021

Study Completion Date

January 12, 2021

Conditions
Interstitial CystitisBladder Pain Syndrome
Interventions
DRUG

SI-722

SI-722 will be intravesically instilled.

DRUG

Placebo

Placebo will be intravesically instilled.

Trial Locations (5)

11530

AccuMed Research Associates, Garden City

32159

Premier Medical Associates, The Villages

77058

Centex Studies, Houston

90017

American Institute of Research, Los Angeles

92562

TriValley Urology Medical Group, Murrieta

All Listed Sponsors
lead

Seikagaku Corporation

INDUSTRY

NCT04208087 - PK and Safety of SI-722 in IC/BPS | Biotech Hunter | Biotech Hunter